Assistant Professor
PhD, HDR
Tel: +33(0)1.80.00.63.35
Area of Research
Neuropharmacology, Neurobiology of Depression/Anxiety, Animal Models of Psychiatric Disorders, Genetics.
Expertise
Expression profiles of genes in limbic areas in animal models of depression: links with human pathology? Gene Networks involved in mood disorders.
Research Theme
I graduated in 2003 and obtained fundings to do pursue with a PhD in neuropharmacology where I studied the mechanism of action of pindolol in its potentiation of effects of antidepressant treatment (Université Paris Sud, France). I obtained my Ph.D. in Neuropharmacology in May 2006 and was awarded for his thesis the same year. From 2006 to 2008, I studied the beneficial effects of nicotine on motor impairment in the 6-OHDA rat model of Parkinson during a first postdoctoral position (Inserm, Paris, France). From 2008 to 2011, I joined Etienne Sibille Lab (University of Pittsburgh, USA), and studied the effects of major depressive disorders on gene expression in the amygdala of depressed subjects and in animal models of the pathology. Since 2011, I am an associate professor, working on the molecular causes of antidepressant treatment resistance in relevant animal models, with the goal of finding peripheral and central biomarkers of response to antidepressant therapies.
Selected Publications
Lebeau, R. H., I. Mendez-David, L. Kucynski-Noyau, C. Henry, D. Attali, M. Plaze, R. Colle, E. Corruble, A. M. Gardier, R. Gaillard, J. P. Guilloux and D. J. David (2022). « Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine. » Front Pharmacol 13: 993449.
Felice, D., J. P. Guilloux, A. Pehrson, Y. Li, I. Mendez-David, A. M. Gardier, C. Sanchez and D. J. David (2018). « Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. » Front Pharmacol 9: 204.
Tritschler, L., M. A. Kheirbek, Y. L. Dantec, I. Mendez-David, J. P. Guilloux, C. Faye, J. Doan, T. H. Pham, R. Hen, D. J. David and A. M. Gardier (2017). « Optogenetic activation of granule cells in the dorsal dentate gyrus enhances dopaminergic neurotransmission in the Nucleus Accumbens. » Neurosci Res.
Mendez-David, I., C. Boursier, V. Domergue, R. Colle, B. Falissard, E. Corruble, A. M. Gardier, J. P. Guilloux and D. J. David (2017). « Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/Depression. » Front Cell Neurosci 11: 237.
Mendez-David, I., J. P. Guilloux, M. Papp, L. Tritschler, E. Mocaer, A. M. Gardier, S. Bretin and D. J. David (2017). « S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms. » Front Pharmacol 8: 462.
Guilloux, J. P., A. M. Gardier and D. J. David (2017). « New targets and modalities of antidepressant drugs development. » La lettre du Pharmacologue 31(1): 12-18.
Mekiri, M., A. M. Gardier, D. J. David and J. P. Guilloux (2017). « Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice. » Exp Clin Psychopharmacol 25(2): 94-104.
Guilloux, J. P., B. A. Samuels, I. Mendez-David, A. Hu, M. Levinstein, C. Faye, M. Mekiri, E. Mocaer, A. M. Gardier, R. Hen, A. Sors and D. J. David (2017). « S 38093, a histamine H3 antagonist/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice. » Sci Rep 7: 42946.
Besson, M., S. Guiducci, S. Granon, J. P. Guilloux, B. Guiard, C. Reperant, P. Faure, S. Pons, G. Cannazza, M. Zoli, A. M. Gardier and U. Maskos (2016). « Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments. » Psychopharmacology (Berl) 233(18): 3297-3314.
Darcet, F., A. M. Gardier, R. Gaillard, D. J. David and J. P. Guilloux (2016). « Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease. » Pharmaceuticals (Basel) 9(1).
David D. J., L. Tritschler, J. P. Guilloux, A. M. Gardier, C. Sanchez, R. Gaillard (2016). « Pharmacological properties of vortioxetine and its pre-clinical consequences. » Encéphale. 42: 1S12
Costemale-Lacoste, J. F., J. P. Guilloux and R. Gaillard (2016). « The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: a review of the literature. » Encephale In Press.
Darcet, F., A. M. Gardier, D. J. David and J. P. Guilloux (2016). « Chronic 5-HT receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression. » Neurosci Lett 616: 197-203.
Siopi, E., M. Denizet, M. M. Gabellec, F. de Chaumont, J. C. Olivo-Marin, J. P. Guilloux, P. M. Lledo and F. Lazarini (2016). « Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice. » J Neurosci 36(2): 518-531.
Quesseveur, G., A. C. Petit, H. T. Nguyen, L. Dahan, R. Colle, S. Rotenberg, I. Seif, P. Robert, D. David, J. P. Guilloux, A. M. Gardier, C. Verstuyft, L. Becquemont, E. Corruble and B. P. Guiard (2016). « Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. » Neuropharmacology 105: 142-153.
Colle, R., F. Gressier, C. Verstuyft, E. Deflesselle, J. P. Lepine, F. Ferreri, P. Hardy, J. P. Guilloux, A. C. Petit, B. Feve, B. Falissard, L. Becquemont and E. Corruble (2015). « Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. » J Affect Disord 175C: 233-240.
Guilloux, J. P., S. Bassi, Y. Ding, C. Walsh, G. Turecki, G. Tseng, J. M. Cyranowski and E. Sibille (2015). « Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. » Neuropsychopharmacology 40(3): 701-710.
Ding, Y., L.-C. Chang, W. Wang, J.-P. Guilloux, J. Parrish, H. Oh, B. J. French, D. A. Lewis, G. C. Tseng and E. Sibille (2015). « Molecular and Genetic Characterization of Depression: Overlap with Other Psychiatric Disorders and Aging. » Molecular Neuropsychiatry 1(1): 1-12.
Tritschler, L., D. Felice, R. Colle, J. P. Guilloux, E. Corruble, A. M. Gardier and D. J. David (2014). « Vortioxetine for the treatment of major depressive disorder. » Expert Rev Clin Pharmacol: 1-15.
Darcet, F., I. Mendez-David, L. Tritschler, A. M. Gardier, J. P. Guilloux and D. J. David (2014). « Learning and memory impairments in a neuroendocrine mouse model of anxiety/depression. » Front Behav Neurosci 8: 136.
Le Dantec, Y., G. Hache, J. P. Guilloux, B. P. Guiard, D. J. David, J. Adrien and P. Escourrou (2014). « NREM sleep hypersomnia and reduced sleep/wake continuity in a neuroendocrine mouse model of anxiety/depression based on chronic corticosterone administration. » Neuroscience 274: 357-368..
Guilloux, J. P., I. Mendez-David, A. Pehrson, B. P. Guiard, C. Reperant, S. Orvoen, A. M. Gardier, R. Hen, B. Ebert, S. Miller, C. Sanchez and D. J. David (2013). « Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. » Neuropharmacology 73: 147-159.
Douillard-Guilloux, G., J. P. Guilloux, D. A. Lewis and E. Sibille (2013). « Anticipated brain molecular aging in major depression. » Am J Geriatr Psychiatry 21(5): 450-460.
Xia, L., C. Delomenie, I. David, Q. Rainer, M. Marouard, H. Delacroix, D. J. David, A. M. Gardier and J. P. Guilloux (2012). « Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT(1)A and 5-HT(1)B receptors disruption in mice. » Neuroscience letters 521(1): 20-25.
Besson, M., V. David, M. Baudonnat, P. Cazala, J. P. Guilloux, C. Reperant, I. Cloez-Tayarani, J. P. Changeux, A. M. Gardier and S. Granon (2012). « Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. » Psychopharmacology 220(1): 1-14.
Guilloux, J. P., G. Douillard-Guilloux, R. Kota, X. Wang, A. M. Gardier, K. Martinowich, G. C. Tseng, D. A. Lewis and E. Sibille (2012). « Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. » Molecular psychiatry 17(11): 1130-1142.
Tripp, A., H. Oh, J. P. Guilloux, K. Martinowich, D. A. Lewis and E. Sibille (2012). « Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. » The American journal of psychiatry 169(11): 1194-1202.
Guilloux, J. P., D. J. David, L. Xia, H. T. Nguyen, Q. Rainer, B. P. Guiard, C. Reperant, T. Deltheil, M. Toth, R. Hen and A. M. Gardier (2011). « Characterization of 5-HT(1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments. » Neuropharmacology 61(3): 478-488.
Rainer, Q., L. Xia, J. P. Guilloux, C. Gabriel, E. Mocaer, R. Hen, E. Enhamre, A. M. Gardier and D. J. David (2011). « Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. » Int J Neuropsychopharmacol: 1-15.
Guilloux, J. P., M. Seney, N. Edgar and E. Sibille (2011). « Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: Relevance to emotionality and sex. » J Neurosci Methods 197(1): 21-31.
Guilloux JP, Gaiteri C, Sibille E. (2010). «Network analysis of positional candidate genes of schizophrenia highlights…more than… myelin-related pathways. Mol Psychiatry». Aug;15(8):786-8.
Gaiteri C, Guilloux JP, Lewis DA, Sibille E. (2010) «Altered Gene Synchrony Suggests a Combined Hormone-Mediated Dysregulated State in Major Depression». PLoS One. Apr 1;5(4):e9970
Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A, Prémont J. (2010). Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One. Mar 19;5(3):e9777.
Massart, R., J. P. Guilloux, V. Mignon, P. Sokoloff and J. Diaz (2009). « Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. » Eur J Neurosci 30(3): 397-414.
Guilloux, J. P., D. J. David, B. P. Guiard, F. Chenu, C. Reperant, M. Toth, M. Bourin and A. M. Gardier (2006). « Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice. » Neuropsychopharmacology 31(10): 2162-2172.
Book Chapters
Mendez-David, I., D. J. David, J.-P. Guilloux, R. Hen and A. M. Gardier (2015). « 5-HT4 Receptor Subtype, β-Arrestin Level, and Rapid-Onset Effects of Antidepressant Drugs. » 95: 101-121.
David, D. J., B. P. Guiard, J. P. Guilloux and A. M. Gardier (2013). Pharmacologie des antidépresseurs : modèles animaux. Les Antidépresseurs. E. Corruble. Paris, Flammarion Médecine/Sciences: 40-51.
Guilloux, J. P., D. J. David, B. A. Samuels, I. David, A. M. Gardier and B. P. Guiard (2012). Non-response to initial antidepressant therapy. Psychology. Rijeka, Croatia, InTech.
Deltheil, T., B. Guiard, J. P. Guilloux, D. David, F. Coudore and A. M. Gardier (2012). Sérotonine et facteurs neurotrophiques dans la dépression. Sérotonine: aspects biologiques et cliniques. O. Spreux-Varoquaux. Paris, Lavoisier – Médecine Sciences. 1: 329-370.